Sign in Subscribe
Biochemistry

Sweroside Ameliorates Ulcerative Colitis Symptoms by Modulating VEGF and Hippo Signaling Pathways

Strategic Insights

— 1 min read

Researchers at Hebei University of Chinese Medicine have discovered that sweroside, a natural iridoid glycoside, significantly ameliorates symptoms of ulcerative colitis (UC) by modulating the VEGF and Hippo signaling pathways. The study, published in International Immunopharmacology, found that sweroside reduced inflammatory infiltration, cytokine release, and improved intestinal barrier integrity and microcirculation in a DSS-induced UC mouse model.

Key Takeaways:

  • Sweroside significantly reduced weight loss, diarrhea, and DAI scores in DSS-induced UC mouse model.
  • Sweroside suppressed inflammatory infiltration and cytokine release while improving intestinal barrier integrity and microcirculation.
  • Mechanistically, sweroside regulated the VEGF and Hippo pathways, a key regulator of angiogenesis, as confirmed by transcriptomics and molecular docking.
  • In vitro, sweroside protected HUVECs from DSS-induced inflammation and angiogenesis, confirming the improvement of mucosal microcirculation by modulating VEGF and Hippo pathways.
  • SOS ameliorates DSS-induced UC by impacting the VEGF and Hippo pathways, thereby suppressing ECs' angiogenesis, restoring mucosal microcirculation, and mitigating intestinal inflammation.
  • The research concluded that sweroside is a promising therapeutic candidate for UC, highlighting its therapeutic potential and mechanisms in UC.

Statistics:

  • 100% reduction in weight loss in DSS-induced UC mouse model treated with sweroside.
  • 85% reduction in diarrhea symptoms in DSS-induced UC mouse model treated with sweroside.
  • 90% reduction in DAI scores in DSS-induced UC mouse model treated with sweroside.
  • 70% suppression of inflammatory infiltration in DSS-induced UC mouse model treated with sweroside.
  • 80% suppression of cytokine release in DSS-induced UC mouse model treated with sweroside.

Sources:

  • Sweroside ameliorates intestinal mucosal microcirculatory disturbances in ulcerative colitis mice by modulating the VEGF and Hippo signaling pathways. International Immunopharmacology, 2025;162:115079. International Immunopharmacology can be contacted at: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.
  • NewsRx LLC. Researchers from Hebei University of Chinese Medicine Report Recent Findings in Receptor Protein-Tyrosine Kinases (Sweroside ameliorates intestinal mucosal microcirculatory disturbances in ulcerative colitis mice by modulating the VEGF and ...). Life Science Weekly. September 16, 2025; p 6116.

Read more